Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% SPL 7013 gel (VivaGel(®)) to assess expanded safety

OBJECTIVE: The aim of this study was to examine the effect of the 3% SPL 7013 gel (VivaGel(®)) on mucosal immune markers hypothesized to be associated with HIV-1 acquisition. DESIGN: Phase 1, placebo-controlled, randomized, double-blind clinical trial was performed in 54 young women in the U.S. and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: MOSCICKI, Anna-Barbara, KAUL, Rupert, Yifei, MA, SCOTT, Mark E., DAUD, Ibrahim I., BUKUSI, Elizabeth A., SHIBOSKI, Stephen, REBBAPRAGADA, Anuradha, HUIBNER, Sanja, COHEN, Craig R.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3261360/
https://ncbi.nlm.nih.gov/pubmed/22067666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e31823f2aeb
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky